US Bankruptcy Chapter 11 Insolvency SEC Filings — July 16, 2026

Court confirmation of Chapter 11 plan eliminates all equity value; existing shares canceled with zero distribution to shareholders

Nasdaq delisting completed on July 10, 2026; shares now trade OTC under NOTVQ, severely limiting liquidity and institutional access

Prepackaged plan approved by court on July 14, 2026; emergence expected as private company, removing any public market recovery path

5,100,000 new shares and 630,337 warrants issued exclusively to prepetition lenders/noteholders; no equity participation for former shareholders

Joint administration of cases under 'In re Inotiv, Inc., et al.' in Southern District of Texas; no insider trading activity reported, indicating management had no confidence in recovery

No period-over-period comparisons available as filing is a single event; no revenue, margin, or operational data to assess turnaround potential

No forward-looking guidance or capital allocation plans disclosed; company exits public markets with no shareholder return prospects

Sentiment analysis rated 'negative' with materiality 10/10; this is a total loss event with no upside for equity holders

All 35,172,908 common shares canceled with zero recovery; shareholders face total loss of investment

Nasdaq suspended trading on June 11, 2026; Form 25 filed July 10, 2026; deregistration effective 90 days later, eliminating public trading

Shares now trade OTC under NOTVQ; severely reduced liquidity and no institutional coverage expected

Prepackaged plan gives all new equity to lenders; no distribution to existing equity holders, confirming zero recovery value

Company emerges as private entity; no public financial disclosures or investor communications going forward

No insider buying or selling reported; management likely had no personal stake or confidence in equity recovery

No operational or financial guidance provided; company's future performance is opaque

No dividends, buybacks, or splits disclosed; company is in restructuring mode with no shareholder return policy

Prepetition lenders receiving 5,100,000 new shares and warrants; potential for value if reorganized company performs well as private entity

Speculative traders may attempt to trade NOTVQ for short-term volatility, though zero fundamental recovery expected

Prepackaged plan approval within ~1 month of filing shows efficient restructuring; may signal similar speed for other distressed companies

Inotiv's failure may indicate broader stress in contract research or life sciences tools sector; watch for other distressed names

Former shareholders may explore legal action against board/management for breach of fiduciary duty; potential for derivative litigation

Reorganized company may attract private equity interest if core business has value; no public disclosure to assess

Prior to delisting, short sellers may have profited; no current opportunity as equity is worthless

Inotiv's prepackaged plan confirms that equity holders often receive zero recovery in Chapter 11, especially when debt is high and assets are insufficient. This pattern is common in distressed restructurings.

Inotiv's plan confirmation within ~1 month of filing highlights the efficiency of prepackaged bankruptcies, which can reduce legal costs and uncertainty for creditors.

Nasdaq delisting on July 10, 2026, and OTC trading under NOTVQ, shows how exchange rules accelerate equity value destruction in bankruptcy.

Inotiv's emergence as a private company reflects a growing trend where reorganized firms avoid public market scrutiny and regulatory costs.

The absence of insider trading in Inotiv's filing is typical for bankrupt companies, as insiders have no incentive to buy worthless equity.

SEC deregistration under Section 12(b) effective 90 days after July 10, 2026; watch for final filing and cessation of public reporting [October 2026]

Monitor NOTVQ for any speculative volume or price movements; zero fundamental value expected [Ongoing]

Watch for any press releases on reorganized company's operations or new investors [Post-confirmation]

Monitor if lenders sell new shares or warrants in private transactions [Ongoing]

Watch for other contract research or life sciences tools companies showing financial distress [Ongoing]

Monitor for shareholder lawsuits against board/management for breach of fiduciary duty [Ongoing]

Track broader bankruptcy filings in the sector to identify systemic risks [Ongoing]